AnaptysBio (NASDAQ:ANAB) Price Target Raised to $85.00 at Stifel Nicolaus

AnaptysBio (NASDAQ:ANAB) had its target price raised by Stifel Nicolaus from $56.00 to $85.00 in a research note issued to investors on Thursday, Marketbeat Ratings reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities research analysts also recently weighed in on ANAB. Wells Fargo & Company upped their price target on shares of AnaptysBio from $51.00 to $81.00 and gave the company an “overweight” rating in a report on Wednesday, November 5th. Wall Street Zen cut shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a report on Friday, January 23rd. Barclays lifted their price target on shares of AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research report on Wednesday. Guggenheim reaffirmed a “buy” rating on shares of AnaptysBio in a report on Thursday, December 18th. Finally, Truist Financial raised their price objective on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $71.89.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $57.28 on Thursday. AnaptysBio has a 1 year low of $15.32 and a 1 year high of $63.47. The firm has a market cap of $1.65 billion, a P/E ratio of -110.15 and a beta of 0.32. The stock has a fifty day moving average price of $50.17 and a two-hundred day moving average price of $38.78.

AnaptysBio (NASDAQ:ANAB) last posted its quarterly earnings data on Monday, March 9th. The biotechnology company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $0.89 by $0.69. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 5.64%.The company had revenue of $108.25 million for the quarter, compared to the consensus estimate of $87.09 million. On average, research analysts predict that AnaptysBio will post -6.08 earnings per share for the current fiscal year.

AnaptysBio declared that its board has approved a share repurchase program on Friday, November 21st that permits the company to repurchase $100.00 million in shares. This repurchase authorization permits the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s board believes its stock is undervalued.

Insider Activity at AnaptysBio

In other news, insider Paul F. Lizzul sold 3,650 shares of AnaptysBio stock in a transaction on Thursday, January 8th. The stock was sold at an average price of $44.71, for a total transaction of $163,191.50. Following the transaction, the insider owned 42,088 shares in the company, valued at approximately $1,881,754.48. The trade was a 7.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Faga sold 14,281 shares of the company’s stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $44.71, for a total value of $638,503.51. Following the transaction, the chief executive officer directly owned 479,344 shares in the company, valued at $21,431,470.24. The trade was a 2.89% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 156,280 shares of company stock worth $7,254,939. Insiders own 33.50% of the company’s stock.

Hedge Funds Weigh In On AnaptysBio

Several institutional investors and hedge funds have recently bought and sold shares of ANAB. Smartleaf Asset Management LLC increased its holdings in shares of AnaptysBio by 5,864.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 835 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 821 shares during the period. Larson Financial Group LLC grew its position in AnaptysBio by 54.6% during the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares in the last quarter. Bessemer Group Inc. grew its position in AnaptysBio by 950.0% during the third quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares in the last quarter. Tower Research Capital LLC TRC increased its stake in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the period. Finally, Osaic Holdings Inc. increased its stake in AnaptysBio by 11,630.0% in the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 2,326 shares during the period.

Key AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $85 and reiterated a Buy rating, signaling substantial upside vs. current levels. Stifel Nicolaus price-target raise
• Positive Sentiment: Barclays raised its target to $79 and moved to an Overweight rating, another institutional endorsement that supports upside expectations. Barclays price-target raise
• Positive Sentiment: H.C. Wainwright boosted its target to $66 and kept a Buy rating; the firm’s analyst also published a long‑range FY2030 EPS projection (~$7.67), which is far above current consensus and implies strong optionality from AnaptysBio’s assets. H.C. Wainwright price-target raise HC Wainwright FY2030 note
• Neutral Sentiment: AnaptysBio announced a spin‑off of its biopharma portfolio — a strategic move that can unlock value long term but often creates short‑term uncertainty until details (timing, tax treatment, assets) are disclosed. Spin-off announcement
• Neutral Sentiment: Short‑interest reports show a reported “large increase” but list zero shares and NaN changes — data appears inconsistent and likely not a meaningful signal. (Treat short‑interest data as noisy/uncertain until clarified.)
• Negative Sentiment: Despite positive analyst action, intraday selling and higher-than-average volume suggest profit‑taking or rotation away from a stock that recently traded near its 1‑year high; that technical flow can drive near‑term downside even with favorable analyst commentary.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.